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The Use of Clopidogrel in Carotid Endarterectomy:
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Clopidogrel is commonly encountered in patients presenting for carotid endarterectomy (CEA). Its use around this time is
controversial and there is no randomized control trial data to determine best practice. Questionnaires were posted to all
members of the Vascular Society investigating clopidogrel use at the time of CEA. 52% discontinue clopidogrel preopera-
tively, with 51% of those using no alternative and 49% replacing it with aspirin. Clopidogrel use is not related to the num-
ber of endarterectomies performed by each surgeon.
There is no consensus on clopidogrel use during CEA. This highlights the need for quality prospective data on this
subject.
 2007 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
Keywords: Clopidogrel; Antiplatelet agents; Carotid endarterectomy; UK Carotid Endarterectomy database; Carotid
endarterectomy complications.Introduction
Clopidogrel is a drug commonly encountered in
patients presenting for carotid endarterectomy
(CEA).1,2 It is, however, associated with an increased
risk of bleeding,3,4 and the manufacturers advise cau-
tion with its use around the time of elective surgery.5
They recommend stopping clopidogrel for 5 to 7 days
prior to elective surgery unless an anti-platelet effect
is desired.
Currently there is no consensus amongst surgeons
regarding the use of clopidogrel at the time of CEA
where the risk of increased bleeding must be balanced
against the risk of perioperative cerebrovascular
events. There is no published evidence demonstrating
an association between clopidogrel and either benefi-
cial or harmful effects at the time of CEA.
Report
The aim of this study was to assess current practice
of members of the Vascular Society regarding the
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tionnaire was sent to all consultants who were
members of the Vascular Society in 2004. A record
was kept of respondents and the questionnaire was
sent once only. Respondents were asked how many
carotid endarterectomies they performed annually
along with questions directly related to their policy
on clopidogrel.
From a total of 365 questionnaires sent, 235 were
returned giving a response rate of 64.5%. All respon-
dents were consultant vascular surgeons and 49 did
not perform CEA.
Of the 186 surgeons who performed CEA, 17%
(n¼ 33) performed less than 10 cases annually, 63%
(n¼ 117) performed 10 to 30 and 20% (n¼ 36) per-
formed greater than 30. Surgeons were asked about
their policy on clopidogrel use at the time of CEA.
If a patient were on clopidogrel alone, 48% (n¼ 89)
would continue clopidogrel whilst 52% (n¼ 97)
would discontinue it. Those who continued clopi-
dogrel were asked what they would do if a patient
was on both clopidogrel and aspirin before CEA.
40% (n¼ 35) would continue both, 52% (n¼ 47)
would discontinue clopidogrel and 8% (n¼ 7) would
discontinue clopidogrel and use an alternative
agent.lar Surgery. Published by Elsevier Ltd. All rights reserved.
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49% (n¼ 47) replaced clopidogrel with aspirin and
51% (n¼ 50) used no alternative. Those who changed
clopidogrel to aspirin were asked what they would do
if the patient was genuinely aspirin intolerant. 36%
(n¼ 17) would continue with clopidogrel, 49% (n¼ 23)
would discontinue clopidogrel and 15% (n¼ 7) would
seek an alternative agent. These results are summar-
ised in (Fig. 1).
The number of CEAs performed annually by each
surgeon was matched to clopidogrel prescription to
determine whether volume of cases influenced prac-
tice. There was no correlation between CEA case vol-
ume and clopidogrel policy (Fig. 2).
Discussion
The use of clopidogrel around the time of CEA is con-
tentious, with some surgeons continuing it to help
prevent thrombotic events, and others stopping it to
avoid the risk of perioperative bleeding. We surveyed
the vascular surgical community in the UK to deter-
mine whether there was any consensus on this issue.
This was a postal study and it produced a 65% re-
sponse rate. Whilst the limitations of this are accepted,
it did generate replies from 235 vascular surgeons,
representing a significant cross section of the UK vas-
cular community. It demonstrated that there is no con-
sensus on any aspect of clopidogrel prescription, as
each yes or no option produced an equal response
for either course of action. In addition, the number
of CEAs performed by a surgeon had no bearing on
prescribing policy.
Fig. 1. Summarised results.There is currently no published evidence linking clo-
pidogrel use with either perioperative vascular events
or haematoma formation in carotid endarterectomy.
Most data on bleeding risk comes from the cardiotho-
racic literature where significant increases in chest
drain output and re-exploration rates were demon-
strated in patients on clopidogrel although this had
no effect on peri-operative mortality or length of
hospital stay.3,4
There is therefore an urgent need for quality data
on this topic. The UK CEA database is a registry of
CEA to which all vascular surgeons have been invited
to contribute. Part of the data collection deals with
antiplatelet use around the time of CEA, whether
such agents are discontinued and if so when. It also
documents specific complications such as return to
theatre for bleeding, perioperative CVA and cardiac
events and thus such events will be able to be
matched to antiplatelet use. When this study reports
there may, therefore, be evidence for the optimal use
of clopidogrel at the time of CEA. However, the
only way to definitively answer this question is to
conduct a prospective randomised control trial. In
the meantime, there is, unfortunately, no evidence to
determine best practice.
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Fig. 2. Number of CEA performed per annum compared
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